AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
=== Borderlands and studio expansion (2009–2015) === Work on a new intellectual property, Borderlands, began around 2005 and was first announced in 2007. Pitchford likened the game as a combination of computer role-playing games such as Diablo and NetHack, and first-person shooters like Duke Nukem. Defining features of Borderlands was its outlined graphical style and its procedurally-generated loot system that was capable of generating millions of different guns and other gear items. Borderlands was released in October 2009, published by 2K, a subsidiary of Take-Two Interactive. By August 2011, had sold over 4.5 million copies, making it a critical success for Gearbox and allowing it to expand the studio and budgets for subsequent games. Subsequently, Gearbox developed two additional games in the video game series, Borderlands 2 (2012) and Borderlands 3 (2019), as well as the spin-off title Tiny Tina's Wonderlands (2022), and the series has spawn additional games from other studios under 2K/Take-Two or through license, including Borderlands: The Pre-Sequel by 2K Australia, and Tales from the Borderlands from Telltale Games. Gearbox and Take-Two have also partnered with Lionsgate to develop a live-action Borderlands film, which was released on August 9, 2024. In July 2013, Gearbox announced plans to rerelease Homeworld and Homeworld 2 in high definition for modern PC platforms, in addition to making it available through digital distributors.
==== Engineered bacteria-based platform ==== Bacteria have long been used in cancer treatment. Bifidobacterium and Clostridium selectively colonize tumors and reduce their size. Recently synthetic biologists reprogrammed bacteria to sense and respond to a particular cancer state. Most often bacteria are used to deliver a therapeutic molecule directly to the tumor to minimize off-target effects. To target the tumor cells, peptides that can specifically recognize a tumor were expressed on the surfaces of bacteria. Peptides used include an affibody molecule that specifically targets human epidermal growth factor receptor 2 and a synthetic adhesin. The other way is to allow bacteria to sense the tumor microenvironment, for example hypoxia, by building an AND logic gate into bacteria. Then the bacteria only release target therapeutic molecules to the tumor through either lysis or the bacterial secretion system. Lysis has the advantage that it can stimulate the immune system and control growth. Multiple types of secretion systems can be used and other strategies as well. The system is inducible by external signals. Inducers include chemicals, electromagnetic or light waves. Multiple species and strains are applied in these therapeutics. Most commonly used bacteria are Salmonella typhimurium, Escherichia coli, Bifidobacteria, Streptococcus, Lactobacillus, Listeria and Bacillus subtilis. Each of these species have their own property and are unique to cancer therapy in terms of tissue colonization, interaction with immune system and ease of application.
Detention Centers run by the Assad government have been one of the most glaring human rights abuses in Syria. In 2014, the Caesar Report showed gruesome photographs smuggled out of a Syria detention center showed "the systematic killing of more than 11,000 detainees by the Syrian government in one region" during a two and a half year period of the Syria Civil War. A 2016 United Nations investigative report described the detainees in Syrian prisons as suffering under "inhuman living conditions" characterized by unclean environment, lack of sanitation and food as well as systematic torture. Following the death of prisoners in custody, fake certificates were often distributed by the government to claim that the prisoners "died of natural causes". The report further denounced Assad regime's policies of torture and summary executions in detention centres as "extermination as a crime against humanity". Syrian dungeons have been compared to the Nazi extermination camps of World War II, due to the scale of torture and mass killings going on in its prison networks. Journalist Russ Wellen reports that the "state killing machine exceeds the capacity of the system to process". In 2017 details emerged about Sednaya Prison, a military prison near Damascus operated by the Assad government. The prison has been used to hold thousands of prisoners, both civilian and government opposition. Amnesty International estimated that between 5,000 and 13,000 people were extrajudicially executed at the one prison between September 2011 and December 2015.
Sources: en.wikipedia.org
=== Crash === Soon after the big boom, the first problems started to appear. There were problems getting products approved by the FDA and if they got approved there were often difficulties in getting insurance providers to pay for the products and getting it accepted by health care providers. For example, organogenesis ran into problems marketing its product and integrating its product in the health system. This partially due to the difficulties of handling living cells and the increased difficulties faced by physicians in using these products over conventional methods. Another example would be Advanced Tissue Sciences Dermagraft skin product which could not create a high enough demand without reimbursements from insurance providers. Reasons for this were $4000 price-tag and the circumstance that Additionally Advanced Tissue Sciences struggled to get their product known by physicians. The above examples demonstrate how companies struggled to make profit. This, in turn, lead investors to lose patience and stopping further funding. In consequence, several Tissue Engineering companies such as Organogenesis and Advanced Tissue Sciences filed for bankruptcy in the early 2000s. At this time, these were the only ones having commercial skin products on the market.
== History == Lactobacillus delbrueckii subsp. bulgaricus was first identified in 1905 by Stamen Grigorov, who named it Bacillus bulgaricus. Ilya Metchnikoff, a professor at the Pasteur Institute in Paris, researched the relationship between the longevity of Bulgarians and their consumption of yogurt. He had the idea that aging is caused by putrefactive activity, or proteolysis, by microbes that produce toxic substances in the intestine. Proteolytic bacteria such as clostridia, which are part of the normal intestinal flora, produce toxic substances including phenols, ammonia and indols by digestion of proteins. These compounds are responsible for what Metchnikoff called intestinal auto-intoxication, which, according to him, was the cause of the physical changes associated with old age. It was already known at that time that fermentation with lactic acid bacteria inhibits the deterioration of milk because of its low pH. Metchnikoff's research also noted that rural populations in Southeastern Europe and the Russian steppes daily consume milk fermented with lactic acid bacteria and live relatively longer than other populations. Based on these data Metchnikoff proposed that consumption of fermented milk seeds the intestine with harmless lactic acid bacteria increasing intestinal acidity and suppressing the growth of proteolytic bacteria. His results were questioned after a 1920 study showed that the bacterium could not survive in the human intestines, but the idea nevertheless started the research into actually useful probiotics.
=== Bioplastics === Various polymers can be created from algae, which can be especially useful in the creation of bioplastics. These include hybrid plastics, cellulose-based plastics, poly-lactic acid, and bio-polyethylene. Several companies have begun to produce algae polymers commercially, including for use in flip-flops and in surf boards. Even algae is also used to prepare various polymeric resins suitable for coating applications.
Nescafé is a brand of instant coffee sold by the multinational food and drink corporation Nestlé. It comes in many different forms. The name is a portmanteau of the words "Nestlé" and "café". Nestlé first introduced their flagship coffee brand in Switzerland on April 1, 1938.
Sources: en.wikipedia.org
Seeing her escape avenue, Owens agreed and vacuumed the house to indicate her acquiescence to becoming an extended member of the family. Later that day, Owens escaped from a launderette she and Rose had entered and returned home. Although initially too ashamed to divulge what had happened, when her mother noted the welts, bruises and exposed subcutaneous tissues on her daughter's body, Owens burst into tears and confided her ordeal. Owens' mother immediately reported her daughter's story to police, and the Wests were arrested and charged with assault, indecent assault, actual bodily harm and rape. The case was tried at Gloucester Magistrates Court on 12 January 1973, but by this date Owens had decided she could not face the ordeal of giving testimony. All charges pertaining to her ordeal were dropped, and the Wests agreed to plead guilty to the reduced charges of indecent assault and causing actual bodily harm. Rose and Fred were each fined £50 (equivalent to £1,000 in 2025) and the couple were allowed to walk free. When Owens heard this news, she attempted suicide.
==== UK ==== After the Brexit transition period, the regulation regarding edible insects changed in the United Kingdom on 21 January 2021, making them non-marketable without authorization. Insect food products that had been on the market had to be recalled. Insect food products have to be authorized by the Food Standards Agency (FSA) in a novel food authorization process. In February 2022, UK insect industry association Woven Network CIC submitted a first dossier for the authorization of house crickets (Acheta domesticus) as novel food to the FSA.
== Treatment == Treatment is not specific and consists of management of symptoms. Management includes physical therapy for neuropathy and ataxia, educational guidance for writing and reading problems, and speech therapy for dysarthric speech and cognitive impairment. Lipid-lowering agents and low-cholesterol diet might be useed to control cholesterol levels.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.